ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Biotechnology

Robotic suit, iPS therapy to be tried in spinal cord rehab

TOKYO -- Keio University is joining hands with Cyberdyne to develop treatments for spinal cord injuries that combine induced pluripotent stem cell therapy with the startup's wearable cybersuit.

Cyberdyne's HAL for Medical Use robotic suit will be used to treat spinal-cord injuries.

     The project will proceed in two stages starting this year, with the two parties entering into a partnership agreement Monday.

     First, between 20 to 30 patients, many of whom have suffered from debilitating spinal-cord injuries for half a year, will practice walking while wearing Cyberdyne's robotic assistance suit, called the HAL for Medical Use. These sessions will take place three to five times a week and last an hour each day.

     The suit detects nerve signals generated by the brain instructing the leg to walk, then activates the motorized limbs, aiding motion. The trials will determine how well this form of rehabilitation improves patients' ambulatory functions.

     In addition, Keio professor Hideyuki Okano will conduct clinical trials by summer 2017 in which nerve stem cells grown from iPS cells will be transplanted into patients that gave suffered spinal cord injuries in order to spur growth of new nerve tissue.

     If the results prove positive, Keio and Cyberdyne will commence the second phase a few years later, where chronically handicapped patients unable to recover sufficiently using HAL alone will receive iPS stem cell transplants and resume rehab sessions with HAL.

     Both iPS regenerative therapy and the HAL suit were developed in Japan, with the government recognizing the suit as a medical device in November. Over 100,000 people in Japan are paralyzed or endure other effects of spinal cord injuries. About 5,000 people or more suffer spinal cord injuries each year.

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more